Preventing nausea and vomiting after gynecological laparoscopic surgery by patient-controlled intravenous analgesia with a naloxone admixture
A randomized controlled trial

Haihong Yang, MDa,b, Xuedong Gu, MDa, Meiling Xu, MDc, Guan Yang, MDa, Yunju Rao, MDd, Liang Gao, MDe, Gu Gong, MDa, Siyi He, MD* f

Abstract

Background: Opioid-induced nausea and vomiting are common side effects of patient-controlled intravenous analgesia (PCIA). This study aimed to explore the inhibitory effect of a naloxone admixture on the incidence of sufentanil-induced postoperative nausea and vomiting (PONV).

Methods: A total of 132 Uyghur American Society of Anesthesiologists I and II patients scheduled to undergo elective gynecological laparoscopic surgery were recruited; among these, 120 patients were enrolled and randomly allocated into 4 groups: patients receiving PCIA but no naloxone were included in the control group (group A); patients receiving PCIA with a low-dose naloxone admixture at 0.2 μg·kg⁻¹·h⁻¹ were included in group B; patients receiving PCIA with naloxone admixture at 0.4 μg·kg⁻¹·h⁻¹ were included in group C; patients receiving PCIA with naloxone admixture at 0.6 μg·kg⁻¹·h⁻¹ were included in group D. All patients were administered sufentanil at 0.04 kg⁻¹·h⁻¹, butorphanol at 2 kg⁻¹·h⁻¹, and dexmedetomidine at 0.08 kg⁻¹·h⁻¹ using a PCIA device within 2 days of surgery. The occurrence of nausea and vomiting, visual analogue scores for pain intensity, mean arterial pressure, heart rate, oxygen saturation, pruritus, lethargy, respiratory depression, etc, was recorded at 2, 8, 12, 24, and 48 hours postoperatively.

Results: There was a significant difference in the PONV scores between the groups at 8, 12, and 24 hours after surgery (P < 0.01). At 8 and 12 hours, the score of group C/D was significantly lower than that of group A/B (P < 0.01). At 24 hours after surgery, the PONV score of group B/C/D was significantly lower than that of group A (P < 0.01). No significant difference was observed in the general data and visual analogue scores for postoperative pain between the 4 groups.

Conclusion: Naloxone admixture administered at 0.4 to 0.6 μg·kg⁻¹·h⁻¹ can exert an effective inhibitory effect on the incidence and intensity of PONV in gynecological laparoscopic surgery.

Abbreviations: ASA = American Society of Anesthesiologists, PCIA = patient-controlled intravenous analgesia, PONV = postoperative nausea and vomiting, SpO₂ = oxygen saturation, VAS = visual analogue score.

Keywords: naloxone, patient-controlled intravenous analgesia, postoperative nausea and vomiting

1. Introduction

Postoperative analgesia can reduce complications and mortality by relieving pain.[1] Analgesia is an essential part of painless treatment and is an intrinsic requirement for enhanced recovery after surgery.[2] Patient-controlled intravenous analgesia (PCIA) with opioid analgesics is the most commonly used method for the treatment of moderate or severe postoperative pain.
Regardless of the injection method, the utilization of opioids can produce numerous undesired side effects, including nausea and vomiting, pruritus, dizziness, drowsiness, urinary retention, constipation, dependence, tolerance, cognitive impairment, respiratory depression, and opioid-induced hyperalgesia.

Although these side effects are not life-threatening, unpleasant experiences may result in discomfort and decreased quality of life. Among these side effects, postoperative nausea and vomiting (PONV) is widespread, and frequently so debilitating that patients cannot tolerate with them even would rather be in pain. Amelioration or elimination of side effects, especially PONV, has increasingly become one of the trickiest challenges in acute pain management for anesthesiologists.

PONV is a common complication associated with all types of anesthesia (general, regional, or local) within 24 hours, which may give rise to wound dehiscence, electrolyte imbalance, dehydration, unpleasant experiences, delayed discharge time, additional medical interventions, and higher health care costs. The incidence of PONV ranges from 30% to 50%. In particular, the incidence has reached 80% after gynecological laparoscopic surgery in high-risk patients. Vomiting is a complex nerve reflex, and stimulation of these afferent pathways activates the sensation of vomiting through cholinergic (muscarine), dopaminergic, histamine, or 5-serotonergic receptors. Despite advances in prevention and treatment, PONV is still a concern for many patients undergoing gynecological laparoscopic surgery. The use of opioids, agonists for the classical mu, kappa, and delta opioid receptors, has sharply increased the incidence of PONV in a dose-dependent manner during postoperative pain management.

Naloxone, a widely used opioid receptors antagonist, is mainly used to diagnose and alleviate respiratory depression involving opioid overdose or alcoholism. Some studies have suggested that the combined application of naloxone and opioids may reduce opioid-related side effects. A combination of low-dose epidural naloxone at 0.25 μg·kg⁻¹·h⁻¹ with fentanyl is valid in attenuating undesired side effects, especially PONV, besides enhancing analgesia during the early postoperative period. Intravenous infusion of naloxone at a low dose of 0.25 to 1.65 μg·kg⁻¹·h⁻¹ reduces PONV in children, with greater evidence of its effectiveness as a preventative strategy than in the treatment of existing pruritus. Movafegh et al. also showed that an ultralow dose of naloxone infusion could reduce morphine consumption, as well as the incidence of opioid-induced PONV.

However, not all studies had the same opinion. Administering low-dose naloxone with a PCA solution increased opioid requirement and pain, following the increasing incidence of side effects. A similar conclusion was obtained and confirmed by another study. In another study, the combination of naloxone with morphine in normal saline did not decrease the incidence or severity of PONV. The incidence of opioid-induced side effects in postoperative pediatric patients receiving PCA was not eliminated when the infusion rate of naloxone was ≤1 μg·kg⁻¹·h⁻¹. The main reason for reaching converse conclusions lies in the difference in opioid choice (morphine fentanyl, sufentanil, etc.), the discriminate usage and dosage of naloxone, and the distinct observation indicators of side effects. Thus, there is no consistency and standard on this issue which encouraged us to evaluate the definite effects of a naloxone admixture on the incidence and intensity of sufentanil-induced PONV in gynecological laparoscopic surgery.

2. Methods

2.1. General information
This study was conducted in accordance with the Declaration of Helsinki of 1975, as revised in 2010, and was approved by the Ethics Review Committee of the 950 Hospital. Before the study, each patient’s consent was obtained. The inclusion criteria were as follows: American Society of Anesthesiologists physical status I to II, adult Uyghur women aged ≥18 years, and patients diagnosed with gynecologic benign disease undergoing laparoscopic surgery, general anesthesia, and postoperative PCA. The exclusion criteria included refusal to participate in the trial, entering the intensive care unit after the surgery, reinsertion of the nasogastric tube, cognitive impairment, and receiving steroid or antiemetic treatment within 24 hours before the surgery.

2.2. Study design and setting

General anesthesia for all patients was achieved using midazolam 1 mg, propofol 1.5 mg/kg, sufentanil 0.6 μg/kg, and rocuronium bromide 0.6 mg/kg. Anesthesia was induced for endotracheal intubation by continuously pumping propofol and remifentanil to maintain the depth of anesthesia during the surgery. Intermittent intravenous rocuronium bromide was administered to maintain muscle relaxation. After the surgery, the endotracheal tube was pulled out awake, and PCA was used for postoperative analgesia. The eligible patients were randomly divided into 4 groups by a computer (Fig. 1). Patients receiving PCA but no naloxone were allocated to the control group (group A), and patients receiving PCA with naloxone admixture at a rate of 0.2, 0.4, 0.6 μg·kg⁻¹·h⁻¹ were assigned to groups B, C, and D, respectively. The injection rate of the PCA pump was 0.04 μg·kg⁻¹·h⁻¹ for sufentanil, 2 μg·kg⁻¹·h⁻¹ for butorphanol tartrate, and 0.08 μg·kg⁻¹·h⁻¹ for dexmedetomidine, with a total volume of 100 mL. Self-controlled analgesia was delivered at 0.5 mL each time with an interval of 15 minutes. Before the surgery, each patient was trained to understand the assessment scales used in this study and the methods of using the PCA system.

2.3. Data collection

During the follow-up period, we collected information on the basic vital signs (mean arterial pressure, heart rate, and oxygen saturation [SpO₂]) at 2, 8, 12, 24, and 48 hours after surgery and recorded the patient’s nausea and vomiting score (PONV) and visual analogue score (VAS) at each time period, as well as the number of cases of itching, drowsiness, dizziness, hyperhidrosis, and respiratory depression (respiratory rate, <8 breaths/min or SpO₂, <90%). The PONV scoring standards were as follows: no nausea or vomiting, 0 point; mild nausea, abdominal discomfort, but no vomiting, 2 points; obvious nausea and vomiting but no stomach contents vomiting, 3 points; severe vomiting, stomach contents vomiting that was difficult to control without drugs, 4 points. The VAS recording standards were as follows: according to the analog score scale, 0 points indicated no pain, while 10 points represented the most severe pain. VAS was independently assessed during activity and quiet time, which is denoted by Moving-VAS (M-VAS) and Quiet-VAS (Q-VAS), respectively. Simultaneously, postoperative complications were observed such as pruritus, drowsiness, dizziness, hyperhidrosis, and respiratory depression. Respiratory depression was defined as a respiratory rate of <8 breaths/min or SpO₂ of <90%, which should be dealt with in time. If it persisted, PCA could be stopped and switched to other analgesic methods, along with the termination of the experiment. If PCA is unsatisfactory, non-opioid drugs can be appropriately added to enhance the analgesic effect. If it is ineffective, other analgesic methods should be adopted along with the termination of the experiment.

2.4. Statistics

The required sample size was estimated based on a 50% reported incidence of sufentanil-induced PONV in gynecological laparoscopic surgery. We suppose that naloxone admixture would reduce the incidence of PONV to 20% according to a pilot study, and a minimum of 30 patients per group was
required. All data were processed with SPSS 25.0 or GraphPad Prism 8.0. One-way analysis of variance was used to analyze the data. If the variances were uniform, the Student's t test was applied for pairwise comparison; otherwise, the rank-sum test was used. The \( \chi^2 \) test or Fisher exact test was used for count data. The Kruskal-Wallis test was used for the grade count data. Statistical significance was set at \( P < .05 \).

3. Results

3.1. Patients' characteristics

In total, 132 patients were recruited between March 2021 and August 2021. Twelve patients were excluded because they did not meet the inclusion criteria; therefore, 120 patients were enrolled in this study (Fig. 1). The patient characteristics (American Society of Anesthesiologists classification, age, body mass index, and surgery time) in the 4 groups were not statistically different (Table 1).

3.2. Primary outcome

The incidence and intensity of PONV between each group were not different at 2 and 48 hours after surgery but were different at 8, 12, and 24 hours after surgery (Table 2). Among them, the assessed score of PONV in the C/D group was significantly lower than that of the A/B group at 8 and 12 hours after surgery, with a significant difference \( (P < 0.01) \). In addition, the PONV score of group A was still higher than that of group B/C/D at the 24th hour after surgery \( (P < 0.01) \). No PCIA was stopped for various reasons in either group.

3.3. Secondary outcomes

VAS was applied to evaluate postoperative pain, and VAS data were reported at 2, 8, 12, 24, and 48 hours after surgery. The Q-VAS and M-VAS scores were assessed and recorded separately. The analysis indicated that the VAS recording was similar between the test and control groups at each time point \( (P > .05) \), as shown in Table 3.

After the patients returned to the ward, they were examined at 2, 8, 12, 24, and 48 hours, and the mean arterial pressure, heart rate, and SpO\(_2\) were recorded at each time point (Table 4). The vital signs of the patients in the 4 groups were relatively stable, and no statistical difference was observed \( (P > .05) \). No serious adverse events affecting the patients were observed.

Table 1

| Group | ASA classification | Age | BMI | Surgery time |
|-------|-------------------|-----|-----|-------------|
| A     | 1.27 ± 0.082      | 37.3 ± 2.06  | 24.56 ± 0.46  | 1.74 ± 0.06 |
| B     | 1.30 ± 0.085      | 37.37 ± 1.84 | 24.13 ± 0.41  | 1.69 ± 0.07 |
| C     | 1.23 ± 0.079      | 39.30 ± 1.79 | 23.53 ± 0.33  | 1.61 ± 0.06 |
| D     | 1.20 ± 0.074      | 36.70 ± 1.68 | 24.13 ± 0.34  | 1.64 ± 0.07 |

Values are expressed as mean ± standard error.

ASA = American Society of Anesthesiologists, BMI = body mass index.
Postoperative complications, such as pruritus, drowsiness, dizziness, hyperhidrosis, and respiratory depression, were recorded at various time points in each group. The incidence of complications was analogous, and no statistical difference was observed (P > .05). No respiratory depression occurred, as shown in Table 5.

4. Discussion

This study illustrates that a naloxone admixture infusion at 0.4 to 0.6 μg·kg⁻¹·h⁻¹ opportune decreases the incidence and intensity of sufentanil-induced PONV. This study was carried out at a secondary hospital in the Uyghur-populated area and focused on patients undergoing gynecological laparoscopic surgery who were at a high risk of PONV. In this study, we added a gradient dose of naloxone to manage the development of minimally invasive surgery and the increasing emphasis on early activities and discharge, as well as the objective requirements for enhanced recovery after surgery, opioid-sparing strategy and some new antiemetics have been utilized, but a high incidence of PONV still exists. Clinically, PONV management is divided into drug and nondrug treatments. Drug treatment mainly involves the use of 5 hydroxytryptamine (5-HT3) receptor antagonists, antihistamines, neurokinin 1 (NK-1) receptor antagonists, anticholinergics, and dopamine receptor antagonists. Nondrug prophylaxis involves reducing the fasting time, maintaining water and electrolyte balance, and decreasing the use of inhaled anesthetics. The pharmacologic management of PONV should use a validated risk-scoring system, adjust the risk level of patients, adopt cost-effective methods for high-risk groups, and minimize the possibility of adverse side effects due to drug interactions during the perioperative period. For populations at high risk of PONV, the main preventive measures are local anesthesia or nerve block, intravenous anesthesia if possible, reducing the use of opioids and inhaled anesthetics, and ensuring an appropriate perioperative water supply. In addition, the use of preventive antiemetics, an opioid-sparing strategy combined with multimodal analgesia techniques, is also available. Overall, the use of strategies to lower the baseline risk of PONV (decreasing water deprivation time, reducing opioid usage, and multimodal analgesia) will reduce the likelihood of patients developing PONV.

Uyghur women, particularly the older women, are often nervous and anxious during hospitalization due to differences in language and culture, which virtually increases the incidence of PONV. This study was carried out at a secondary hospital in the Uyghur-populated area and focused on patients undergoing gynecological laparoscopic surgery who were at a high risk of PONV. In this study, we added a gradient dose of naloxone to a PCIA device to explore its possible role in reducing the incidence and intensity of PONV. Previous studies have shown that small doses of naloxone in the epidural space can effectively prevent side effects such as nausea and vomiting caused by opioids, without weakening or even enhancing analgesia. However,

| Table 2 | Postoperative PONV score of patients within 48h. |
|---------|-----------------------------------------------|
| Group   | 2 h   | 8 h   | 12 h  | 24 h  | 48 h  |
| PONV (n = 30) | | | | | |
| A       | 58.05 | 72.00 | 76.03 | 75.05 | 62.92 |
| B       | 63.05 | 69.42 | 66.88 | 58.57 | 57.22 |
| C       | 61.45 | 47.50*| 49.20*| 54.80*| 64.90 |
| D       | 59.45 | 53.08*| 49.88*| 53.58*| 56.97 |
| P value | 0.939 | 0.002 <0.001<0.001 | 0.301 |

The Kruskal-Wallis K independent test was used to assess statistical significance among groups. Data are expressed as average rank. PONV = postoperative nausea and vomiting.

* P < .01.

| Table 3 | Postoperative vital signs of each group. |
|---------|----------------------------------------|
| Item    | Group | 2 h   | 8 h   | 12 h  | 24 h  | 48 h  |
| MAP (mm Hg) | A     | 79.53 ± 12.67 | 77.63 ± 13.26 | 75.12 ± 11.28 | 75.26 ± 10.51 | 72.75 ± 11.24 |
|          | B     | 77.16 ± 10.73 | 79.36 ± 14.46 | 75.16 ± 11.28 | 73.76 ± 13.46 | 70.67 ± 13.23 |
|          | C     | 78.25 ± 13.26 | 78.21 ± 11.78 | 75.36 ± 10.29 | 74.37 ± 14.26 | 69.77 ± 10.12 |
|          | D     | 79.57 ± 12.56 | 77.26 ± 13.47 | 75.12 ± 11.28 | 74.37 ± 14.26 | 69.77 ± 10.12 |
| HR (rpm) | A     | 91.61 ± 13.32 | 83.65 ± 11.67 | 81.22 ± 10.79 | 75.21 ± 10.23 | 71.74 ± 9.89 |
|          | B     | 93.72 ± 11.21 | 85.62 ± 12.79 | 80.25 ± 11.71 | 74.23 ± 11.37 | 70.27 ± 10.26 |
|          | C     | 89.84 ± 15.71 | 82.55 ± 14.27 | 79.23 ± 12.13 | 72.35 ± 11.86 | 72.56 ± 8.37 |
|          | D     | 92.88 ± 13.27 | 83.43 ± 11.82 | 78.46 ± 13.21 | 71.67 ± 12.77 | 71.79 ± 10.39 |
| SpO₂ (%) | A     | 95.21 ± 4.27 | 96.45 ± 3.34 | 97.21 ± 2.31 | 98.21 ± 1.48 | 98.51 ± 1.23 |
|          | B     | 96.23 ± 3.76 | 97.24 ± 2.21 | 96.48 ± 3.07 | 96.78 ± 1.70 | 97.20 ± 1.61 |
|          | C     | 95.56 ± 3.27 | 95.98 ± 2.86 | 96.21 ± 2.90 | 97.21 ± 2.01 | 97.67 ± 1.30 |
|          | D     | 96.34 ± 2.98 | 96.47 ± 3.11 | 97.11 ± 2.78 | 97.56 ± 1.81 | 98.01 ± 1.66 |

Values are expressed as mean ± standard division. HR = heart rate, MAP = mean arterial pressure, SpO₂ = oxygen saturation.
Evidence suggests that the side effects associated with opioids result from the activation of excitatory mu receptors. As mentioned above, naloxone, a nonselective opioid receptor antagonist, may reduce the incidence of side effects associated with opioids, such as itching, drowsiness, dizziness, hyperhidrosis, pruritus, and respiratory depression. However, in this study, we found no statistically significant differences in these side effects between the groups. The underlying reason may be that the mechanisms of the various side effects caused by opioids are not exactly the same. The population study of previous literature was different from the present study, which involved a wide range of subjects, aged 6 to 8 years. Second, the incidence of side effects such as itching, drowsiness, dizziness, hyperhidrosis, and respiratory depression in this study was extremely low or even absent in this study. Coupled with the low sample size and single-center research, this may produce some interference with the true results.

This study has several limitations. This was a single-center study conducted in a secondary hospital and lacked multicenter large-scale clinical trial validation. In addition, the mechanism by which naloxone antagonizes the side effects of opioids requires further investigation.

In conclusion, an admixture of low-dose naloxone at 0.4 to 0.6 μg·kg^{-1}·h^{-1} can better ameliorate the symptoms of PONV caused by opioids in gynecological laparoscopic surgery earlier. The efficacy of naloxone in preventing opioid-induced PONV was identified in this study, suggesting that naloxone may be widely used in clinical practice and may significantly improve the quality of life of patients.

Author contributions
Siyi He designed and performed the study. Haihong Yang, Meiling Xu, Xuedong Gu, Yunju Rao, and Liang Gao collected and analyzed the data. Haihong Yang, Gu Gong, and Siyi He analyzed the results and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgments
Thanks to all the peer reviewers and editors for their valuable opinions and suggestions.

References
[1] Barratt DT, Sia AT, Tan EG, et al. Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Med. 2021;11:2648–2660.
[2] Andres J, Pogatzki-Zahn E, Huygen F, et al. Controlling acute pain to improve the quality of postoperative pain management: an update from the European Society of Regional Anesthesia meeting held in Maastricht (September 2016), Pain Manag. 2017;7:513–22.
[3] Monitto CL, Kost-Byerly S, White E, et al. The optimal dose of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000;92:958–67.
[4] Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology. 2000;92:958–67.
[5] Skledar SJ, Williams BA, Vallejo MC, et al. Eliminating postoperative nausea and vomiting in outpatient surgery with multimodal strategies including low doses of nonselecting, off-patent antiemetics: is “zero tolerance” achievable? ScientificWorldJournal. 2007;7:959–77.
[6] Tao B, Liu K, Wang D, et al. Efect of intravenous oxycodone versus subcutaneous on the incidence of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery. J Clin Pharmacol. 2019;59:1144–50.
[7] Zheng XZ, Cheng B, Luo J, et al. The characteristics and risk factors of the postoperative nausea and vomiting in female patients undergoing laparoscopic sleeve gastrectomy and laparoscopic gynecological surgeries: a propensity score matching analysis. Eur Rev Med Pharmacol Sci. 2021;25:182–9.

Table 4
Postoperative VAS among groups.

| Item       | Group | 2 h     | 6 h     | 12 h    | 24 h    | 48 h    | P value |
|------------|-------|---------|---------|---------|---------|---------|---------|
| Q-VAS      | A     | 66.13   | 66.55   | 69.70   | 57.32   | 60.50   | .524    |
|            | B     | 56.63   | 59.93   | 68.52   | 61.77   | 56.97   | .293    |
|            | C     | 61.35   | 58.32   | 59.33   | 64.65   | 60.52   | .089    |
|            | D     | 57.88   | 57.20   | 53.45   | 58.27   | 64.03   | .097    |
| M-VAS      | A     | 64.33   | 57.32   | 52.60   | 52.20   | 56.60   | .341    |
|            | B     | 64.88   | 60.02   | 62.58   | 63.72   | 60.03   | .089    |
|            | C     | 53.53   | 54.74   | 54.63   | 55.05   | 56.50   | .872    |
|            | D     | 59.25   | 70.02   | 72.18   | 71.03   | 69.20   | .901    |

The Kruskal-Wallis K independent test was used to assess statistical significance among groups. Data are expressed as average rank.

Table 5
Postoperative complications in each group within 48h.

| Item       | Group | 2 h     | 8 h     | 12 h    | 24 h    | 48 h    | P value |
|------------|-------|---------|---------|---------|---------|---------|---------|
| Itching    | A     | 1       | 2       | 1       | 1       | 0       | .010    |
|            | B     | 2       | 2       | 2       | 1       | 0       | .010    |
|            | C     | 0       | 2       | 2       | 1       | 1       | .010    |
|            | D     | 1       | 2       | 1       | 1       | 0       | .010    |
| Lethargy   | A     | 1       | 2       | 2       | 1       | 0       | .872    |
|            | B     | 2       | 2       | 2       | 1       | 0       | .872    |
|            | C     | 3       | 4       | 2       | 2       | 1       | .872    |
|            | D     | 3       | 2       | 2       | 2       | 1       | .872    |
| Dizziness  | A     | 5       | 4       | 2       | 2       | 2       | .872    |
|            | B     | 4       | 4       | 3       | 3       | 2       | .872    |
|            | C     | 4       | 3       | 3       | 2       | 2       | .872    |
|            | D     | 5       | 3       | 2       | 2       | 2       | .872    |
| Sweating   | A     | 1       | 1       | 2       | 1       | 1       | .010    |
|            | B     | 1       | 2       | 1       | 0       | 0       | .010    |
|            | C     | 0       | 1       | 1       | 1       | 1       | .010    |
|            | D     | 2       | 2       | 2       | 1       | 1       | .010    |
| P value    | .901  | .855    | 1.000   | 1.000   | 1.000   | .733    |

The χ² test was employed to assess the incidence of complications among groups in each time period. When the number of observation samples was <5, the Fisher exact test was employed. The P values were all >.05.

similar studies have had opposing opinions. Studies have shown that continuous infusion of naloxone aggravates the pain and increases the use of opioids. The main reasons for reaching converse conclusions are discussed above. In recent years, PCIA has been more widely used in postoperative analgesia, but there are few reports on whether the simultaneous use of low-dose naloxone in PCIA has a similar impact on reducing the incidence of PONV. Previous studies have focused on observing the incidence of PONV rather than the intensity of PONV, which is clinically more relevant.

Studies have shown that the use of naloxone at a concentration of 1 μg·kg^{-1}·h^{-1} did not weaken the analgesic effect and increased the use of opioids. In this study, we set up a control group (group A) and 3 experimental groups (low-dose naloxone gradients, groups B, C, and D). The results showed that the application of naloxone in groups C and D can reduce the incidence and intensity of PONV at 8 hours postoperatively, and the lower dose of naloxone in group B plays a delayed role at 12 hours postoperatively, confirming that a naloxone admixture ameliorates the side effects of PONV caused by opioids. Concurrently, we also analyzed the Q-VAS and M-VAS scores and found that naloxone admixture administered at a rate of 0.2 to 0.6 μg·kg^{-1}·h^{-1} maintained a normal level of analgesia without increasing sufentanil consumption.
[8] Horn CC, Wallisch WJ, Homancs GE, et al. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol. 2014;722:55–66.

[9] Ames WA, Machovec K. An update on the management of PONV in a pediatric patient. Best Pract Res Clin Anaesthesiol. 2020;34:749–58.

[10] Wallen D, Halliday TA, Hultin MR, et al. PONV in bariatric surgery: time for opioid-free anaesthesia. Acta Anaesthesiol Scand. 2017;61:858.

[11] Jorgensen H, Winterslev J, Moenche S, et al. Epidural local anesthetic versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev. 2000:4:CD001893.

[12] Roberts GW, Bekker TB, Carlsson HH, et al. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg. 2005;101:1343–8.

[13] Frank JW, Levy C, Calcatera SL, et al. Naloxone administration in US emergency departments, 2000-2011. J Med Toxicol. 2016;12:148–56.

[14] Dunne RB. Prescribing naloxone for opioid overdose intervention. Pain Manag. 2018;8:197–208.

[15] Leppert W, Zajaczkowska R, Wordliczek J. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opin Pharmacother. 2019;20:511–22.

[16] Nimeeliya Z, Derlin T, Kundil Alungal SR, et al. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Psychiatry Res. 2019;272:450–3.

[17] Nee J, Zakari M, Sugarman MA, et al. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1569–84, e1562.

[18] Ma K, Wu X, Chen Y, et al. Effect of multimodal intervention on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy. J Int Med Res. 2019;47:2026–33.

[19] He F, Jiang Y, Li L. The effect of naloxone treatment on opioid-induced side effects: a meta-analysis of randomized and controlled trials. Medicine (Baltim). 2016;95:e4729.

[20] Elvir-Lazo OL, White PF, Yumul R, Cruz Eng H. Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review. F1000Res. 2020;9:F1000 Faculty Rev-983.

[21] Fu C, Wu T, Shu Q, et al. Acupuncture therapy on postoperative nausea and vomiting in abdominal operation: a Bayesian network meta-analysis. Medicine (Baltim). 2020;99:e20301.

[22] Fu CW, Shu Q, Jiao Y, et al. A comparison of noninvasive and invasive acupuncture in preventing postoperative nausea and vomiting: a protocol for systematic review and Bayesian network meta-analysis. Medicine (Baltim). 2020;99:e21544.

[23] Johnson EG, Nguyen J, Oyler D, et al. Naloxone continuous infusion for spinal cord protection in endovascular aortic surgery leads to higher opioid administration and more pain. J Cardiothorac Vasc Anesth. 2021;35:1148–57.

[24] Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–7.

[25] Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000;84:121–31.

[26] Biju Parvath Kumar P, Yen Y, et al. Intravenous administration and more pain. J Cardiothorac Vasc Anesth. 2021;35:1148–57.

[27] Strang J, McDonald R, Campbell G, et al. Take-home naloxone for the emergency interin management of opioid overdose: the public health application of an emergency medicine. Drugs. 2019;79:1395–418.

[28] Baykara S, Alkan K. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients. Psychiatry Res. 2019;272:450–3.

[29] Nee J, Zakari M, Sugarman MA, et al. Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1569–84, e1562.

[30] Ma K, Wu X, Chen Y, et al. Effect of multimodal intervention on postoperative nausea and vomiting in patients undergoing gynecological laparoscopy. J Int Med Res. 2019;47:2026–33.

[31] He F, Jiang Y, Li L. The effect of naloxone treatment on opioid-induced side effects: a meta-analysis of randomized and controlled trials. Medicine (Baltim). 2016;95:e4729.

[32] Elvir-Lazo OL, White PF, Yumul R, Cruz Eng H. Management strategies for the treatment and prevention of postoperative/postdischarge nausea and vomiting: an updated review. F1000Res. 2020;9:F1000 Faculty Rev-983.

[33] Fu C, Wu T, Shu Q, et al. Acupuncture therapy on postoperative nausea and vomiting in abdominal operation: a Bayesian network meta-analysis. Medicine (Baltim). 2020;99:e20301.

[34] Fu CW, Shu Q, Jiao Y, et al. A comparison of noninvasive and invasive acupuncture in preventing postoperative nausea and vomiting: a protocol for systematic review and Bayesian network meta-analysis. Medicine (Baltim). 2020;99:e21544.

[35] Johnson EG, Nguyen J, Oyler D, et al. Naloxone continuous infusion for spinal cord protection in endovascular aortic surgery leads to higher opioid administration and more pain. J Cardiothorac Vasc Anesth. 2021;35:1148–57.

[36] Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92:502–7.